% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lin:298968,
      author       = {X. Lin and Y. Qiu and A. Soni and M. Stuschke$^*$ and G.
                      Iliakis},
      title        = {{R}eversing regulatory safeguards: {T}argeting the {ATR}
                      pathway to overcome {PARP} inhibitor resistance.},
      journal      = {Molecular therapy. Oncology.},
      volume       = {33},
      number       = {1},
      address      = {[New York]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00397},
      pages        = {200934},
      year         = {2025},
      note         = {Molecular Therapy Oncology (Molecular Therapy Oncology) =
                      2950-3299 (import from CrossRef, PubMed, , Journals:
                      inrepo02.dkfz.de)},
      abstract     = {The development of poly (ADP-ribose) polymerase inhibitors
                      (PARPis) is widely considered a therapeutic milestone in the
                      management of BRCA1/2-deficient malignancies. Since a
                      growing number of cancer treatment guidelines include
                      PARPis, the inevitably emerging PARPi resistance becomes a
                      serious limitation that must be addressed. Targeting the DNA
                      damage response signaling kinase, ATR (ataxia telangiectasia
                      and rad3-related serine/threonine kinase), activated in
                      response to PARPi-induced replication stress, represents a
                      promising approach in fighting PARPi-resistant cancers. The
                      success of this combination therapy in preclinical models
                      has inspired efforts to translate its potential through
                      extensive clinical research and clinical trials. However,
                      the available clinical evidence suggests that PARPi/ATRi
                      combinations have yet to reach their anticipated therapeutic
                      potential. In this review, we summarize work elucidating
                      mechanisms underpinning the effectiveness of ATRi in
                      fighting PARPi resistance and review translational studies
                      reporting efficacy in different types of cancer. Finally, we
                      discuss potential biomarkers of patient selection for
                      customized combinations of PARPi/ATRi treatments.},
      subtyp        = {Review Article},
      keywords     = {ATR inhibitors (Other) / DNA double-stranded breaks (Other)
                      / MT: Regular Issue (Other) / PARP inhibitors (Other) /
                      cancer (Other) / cell-cycle checkpoint (Other) /
                      chemotherapy (Other) / homologous recombination (Other) /
                      replication fork (Other)},
      cin          = {ED01},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39968096},
      pmc          = {pmc:PMC11834088},
      doi          = {10.1016/j.omton.2025.200934},
      url          = {https://inrepo02.dkfz.de/record/298968},
}